Untitled Document
IMW 2011

Meeting Overview

We are pleased to invite you to our educational poster session titled “Myeloma Therapy: Strategies in Evolution,” to be held on 4 May 2011 at the 13th International Myeloma Workshop in Paris, France.

During this interactive poster session reception, leaders in the field will discuss recent advances in the field of myeloma.

Date and Location

4 May 2011
20.30 – 22.00
Salle Soufflot
Carrousel du Louvre
Paris, France

Target Audience

This educational activity is designed for hematologists, oncologists and other healthcare providers actively involved and interested in the management of myeloma.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Explain the mechanism of action of current and emerging therapies for multiple myeloma
  • Evaluate changing outcomes in multiple myeloma based on the emerging use of novel bone-targeted therapies
  • Summarize data surrounding novel agents in the management of relapsed/refractory multiple myeloma and integrate new findings into clinical practice

Faculty

Co-Chairs:
Jesus F. San-Miguel, MD, PhD
Hospital Universitario de Salamanca
Salamanca, Spain

Mario Boccadoro, MD
University of Torino
Torino, Italy

Faculty:
Sagar Lonial, MD
Emory University
Atlanta, Georgia, United States
Gareth J. Morgan, MD, PhD
The Institute of Cancer Research
London, United Kingdom

Poster Discussants:
Melissa Alsina, MD
Marina Bolzoni
Benjamin Djulbegovic, MD, PhD
Martin Kropff, MD
Massimo Offidani, MD
Paul G. Richardson, MD

Agenda

Light dinner will be served
20.30   Welcome Reception and Poster Viewing
  • COMPARE—Results of a Randomized Study to Assess the Renal Safety and Efficacy of Ibandronate and Zoledronate in Multiple Myeloma Patients
    Poster discussant: Martin Kropff, MD
  • Optimizing Bone Disease in Myeloma: Zoledronic Acid Plus Thalidomide Combinations Improves Survival and Bone Endpoints: Results of the MRC Myeloma IX Trial
    Poster discussant: Gareth J. Morgan, MD, PhD
  • The Immunomodulatory Drugs Lenalidomide and Pomalidomide Inhibit Multiple Myeloma-Induced Osteoclast Formation and RANKL/OPG Ratio in Myeloma Microenvironment Targeting the Expression of Adhesion Molecules
    Poster discussant: Marina Bolzoni
  • Comparative Effectiveness of Bisphosphonates in Multiple Myeloma
    Poster discussant: Benjamin Djulbegovic, MD, PhD
  • PANORAMA 2: A Phase II Study of Panobinostat (LBH589) in Combination with Bortezomib (BTZ) and Dexamethasone (DEX) in Patients with Relapsed and BTZ-Refractory Multiple Myeloma (MM)
    Poster discussant: Melissa Alsina, MD
  • Phase Ib Study of Oral Panobinostat (LBH589) plus Intravenous Bortezomib in Patients (Pts) with Relapsed (Rel) or Rel and Refractory (Ref) Multiple Myeloma
    Poster discussant: Jesus F. San-Miguel, MD, PhD
  • Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma: Interim Results of Phase 2 Study
    Poster discussant: Paul G. Richardson, MD
  • Melphalan, Thalidomide and Prednisone (MPT) Combined with Oral Panobinostat in Patients with Relapsed/Refractory MM: A Phase I-II Study
    Poster discussant: Massimo Offidani, MD
  • Phase I Study of Vorinostat, Lenalidomide, and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Excellent Tolerability and Promising Activity in a Heavily Pretreated Population
    Poster discussant: Paul G. Richardson, MD
  • Results of PX-171-003-A1, An Open-Label, Single-Arm, Phase 2 (Ph 2) Study of Carfilzomib (CFZ) in Patients (pts) with Relapsed and Refractory Multiple Myeloma (MM)
    Poster discussant: Sagar Lonial, MD
21.00   Clinical Insights in Bone-Targeted Therapy for Multiple Myeloma
Gareth J. Morgan, MD, PhD
21.30   Emerging Options for Relapsed/Refractory Multiple Myeloma
Sagar Lonial, MD
22.00   Concluding Remarks

Printed Materials

IMW 2011

Organizer

This meeting is a prIME Oncology activity.

Support

Support for this activity has been provided by Novartis Oncology.



Fee Information

There is  no fee to attend this educational activity. Light dinner will be served. Preregistration is not required for this event, however space is limited.